Clinical Trials

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07578116 2026-05-27

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

562 enrolled

Anatomic Stage IV Breast Cancer AJCC v8

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04296162 2026-05-26

ORCHID

Phase 2 Completed

182 enrolled

Breast Neoplasms

NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

16 enrolled

HER2-positive Breast Cancer

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

1,157 enrolled 1 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT06686394 2026-05-22

MK-1022-009

Phase 1/2 Recruiting

81 enrolled

Breast Neoplasms

NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

25 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT00896376 2026-05-15

Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase NA Completed

49 enrolled

Breast Neoplasms

NCT07053085 2026-05-14

A Study of Surgery and Radiotherapy in People With Breast Cancer

178 enrolled

Breast Neoplasms

NCT07581795 2026-05-12

SPECTACLE

140 enrolled

Phase 1/2 Active not recruiting

Advanced HER2-positive Breast Cancer

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

18 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07413939 2026-05-11

BREnnA

Phase 2/3 Recruiting

650 enrolled

HER2-positive Breast Cancer

NCT06876714 2026-05-08

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Phase 3 Recruiting

1,524 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT01042379 2026-05-06

I-SPY

Phase 1/2 Not yet recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07136428 2026-05-06

ASCENdANT

42 enrolled

HER2+ Metastatic Breast Cancer

NCT07220135 2026-05-06

NeoTHERa

100 enrolled

Breast Neoplasms

NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

2,175 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07565324 2026-05-04

UC HER

54 enrolled

Breast Neoplasms

NCT04733118 2026-04-29

PHERGAIN-2

393 enrolled

Breast Neoplasms

NCT07095023 2026-04-29

OPTIMAL-BC

Phase NA Recruiting

112 enrolled

Breast Neoplasms

NCT07102381 2026-04-29

EmpowHER 208

125 enrolled

Breast Neoplasms

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

19 enrolled 26 charts

BreastCNS

HER2-positive Metastatic Breast Cancer

NCT07402473 2026-04-23

EUREKA

50 enrolled

HER2-positive Early-stage Breast Cancer

NCT07545044 2026-04-22

A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

60 enrolled

Breast Neoplasms

NCT03820141 2026-04-20

DTP

51 enrolled 12 charts

Breast Neoplasms

NCT05132582 2026-04-20

HER2CLIMB-05

654 enrolled

Breast Neoplasms

NCT07527806 2026-04-17

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

156 enrolled

Breast Neoplasms

NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT07528898 2026-04-14

Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

100 enrolled

Breast Neoplasms

NCT02705859 2026-04-13

Panther

Phase 1 Completed

26 enrolled

HER2 Positive Breast Cancer

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

BreastGastrointestinalThoracic

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07007559 2026-04-13

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02390427 2026-04-09

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1 Completed

68 enrolled

Breast Neoplasms

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Recruiting

1,800 enrolled

Phase 3 Not yet recruiting

Resectable HER2-positive Breast Cancer

NCT07518173 2026-04-08

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

596 enrolled

HER2-positive Breast Cancer

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

113 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05785741 2026-04-06

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

1,000 enrolled

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

30 enrolled

Breast Neoplasms

NCT04208178 2026-04-02

EPIK-B2

19 enrolled

Advanced HER2+Breast Cancer

NCT05378464 2026-04-01

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

28 enrolled

Breast Neoplasms

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Phase 3 Recruiting

544 enrolled

HER2-positive Breast Cancer

NCT07335081 2026-03-24

ctDNA in HER2+ EBC Neoadjuvant Treatment

60 enrolled

Breast Neoplasms

NCT02654119 2026-03-23

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Phase 2 Completed

20 enrolled 12 charts

Breast Neoplasms

NCT05143970 2026-03-20

CHANCES

BreastGastrointestinalGynecologicThoracic

27 enrolled

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT01613482 2026-03-16

TSARINE

Phase 3 Terminated

13 enrolled